The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferoninducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses [1] [2] [3] [4] [5] [6] [7] . Both the magnitude and breadth of the IFITM proteins' in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model 8 , we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 'Spanish' influenza 9, 10 . Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.
IFITM3 was identified in a functional genomic screen as mediating resistance to influenza A virus, dengue virus and West Nile virus infection in vitro 1 . However, the role of the IFITM proteins in antiviral immunity in vivo is unknown. Therefore, we infected mice that are homozygous for a disruptive insertion in exon 1 of the Ifitm3 gene that abolishes its expression 8 (Ifitm3 2/2 ) with a low-pathogenicity murine-adapted H3N2 influenza A virus (A/X-31). Low-pathogenicity strains of influenza do not normally cause extensive viral replication throughout the lungs, or cause the cytokine dysregulation and death typically seen after infection with highly pathogenic viral strains 9 , at the doses used ( Fig. 1a ). However, low-pathogenicity-infected Ifitm3 2/2 mice became moribund, losing .25% of their original body weight and showing severe signs of clinical illness (rapid breathing, piloerection) 6 days after infection. In comparison, wild-type littermates shed ,20% of their original body weight, before fully recovering ( Fig. 1a, b of infection. However, virus persisted and was not cleared as quickly in Ifitm3 2/2 mice, whose lungs contained tenfold higher levels of replicating virus than the wild-type mice at 6 days post-infection ( Fig. 1c ).
No viral RNA was detected in the heart, brain or spleen of infected wild-type or Ifitm3 2/2 mice over the course of infection, revealing that systemic viraemia was not occurring. Full-genome sequencing of virus removed from the lungs of wild-type and Ifitm3 2/2 mice showed no genetic variation. We demonstrated that IFITM3 protein expression after influenza infection was absent in Ifitm3 2/2 mice but increased substantially in wild-type controls ( Fig. 1b and Supplementary Fig. 1 ). Infection of wild-type and Ifitm3 2/2 mice with a human isolate of pandemic influenza A H1N1 (pH1N1/09) resulted in the same severe pathogenicity phenotype in the Ifitm3 2/2 mice ( Fig. 1a, b ). Mouse embryonic fibroblast (MEF) lines generated from multiple matched littermates demonstrated that Ifitm3 2/2 cells are infected more readily in vitro, and lack much of the protective effects of interferon (IFN). Importantly, the stable restoration of IFITM3 conferred wild-type levels of restriction against either the X-31 strain, or the more pathogenic Puerto Rico/8/34 (PR/8) influenza strain ( Fig. 1d and Supplementary Fig. 2 ). In addition to the role of IFITM3 in restriction of high-pathogenicity H5N1 avian influenza 7 , we also show that it limits infection by recent human influenza A virus isolates and influenza B virus ( Supplementary Fig. 3 ). Therefore, enhanced pathogenesis to diverse influenza viruses is attributable to loss of Ifitm3 expression and consequential changes in immune defence of the lungs. Examination of lung pathology showed fulminant viral pneumonia with substantial damage and severe inflammation in the infected Ifitm3 2/2 mice. Lung pathology was characterized by extensive oedema and red blood cell extravasation, as well as pneumonia, haemorrhagic pleural effusion and multiple, large lesions on all lung lobes ( Fig. 2a, b and Supplementary Fig. 4 ). We note that this pathology is similar to that produced by infection of mice and primates with 1918 H1N1 virus [9] [10] [11] . Given the higher viral load in Ifitm3 2/2 mice and increased replication of influenza A virus in Ifitm3-deleted cells in vitro ( Fig. 1d ), we examined both viral nucleic acid and protein distribution in the lung. Influenza virus infection penetrated deeper into the lung tissue in Ifitm3 2/2 compared to wild-type mice whose infection was primarily restricted to the bronchioles, with minimal alveolar infection. Influenza virus was detected throughout the entire lung in Ifitm3 2/2 sections, spreading extensively in both bronchioles and alveoli ( Fig. 2c ). Histopathology showed marked infiltration of cells and debris into the bronchoalveolar space of Ifitm3 2/2 mice ( Fig. 2b and Supplementary Fig. 4b ). The extent and mechanism of cell damage was investigated by TdT-mediated dUTP nick end labelling (TUNEL) assay, showing widespread cellular apoptosis occurring 6 days postinfection in Ifitm3 2/2 mice, whereas apoptosis in wild-type lungs was very limited ( Supplementary Fig. 4c ). Together, the Ifitm3 2/2 mouse pathology is consistent with infection by high-pathogenicity strains of influenza A virus, where widespread apoptosis occurs by day 6 postinfection, whereas lungs from low-pathogenicity infections were similar to those of wild-type mice, displaying minimal damage 9, 12, 13 .
Analysis of cell populations resident in the lung tissue on day 6 postinfection showed that Ifitm3 2/2 mice had significantly reduced proportions of CD4 1 (P 5 0.004) and CD8 1 T cells (P 5 0.02) and natural killer (NK) cells (P 5 0.0001), but an elevated proportion of neutrophils (P 5 0.007) ( Fig. 3a) . Despite the extensive cellular infiltration ( Supplementary Figs 4b, 5a ), the absolute numbers of CD4 1 T-lymphocytes in the lungs of the Ifitm3 2/2 mice were also lower and neutrophils increased compared to wild-type mice (Supplementary Fig. 6 ). The peripheral blood of infected Ifitm3 2/2 mice showed leukopenia ( Supplementary Fig. 5c ). Blood differential cell counts indicated marked depletion of lymphocytes on day 2 postinfection in the Ifitm3 2/2 mice (P 5 0.04) ( Fig. 3b ), reflecting changes observed previously in high-pathogenicity (but not low-pathogenicity) influenza infections in both humans and animal models 9, 12, 14, 15 . Heightened cytokine and chemokine levels are also hallmarks of severe influenza infection, having been observed in both human and animal models 9, 16 . We observed exaggerated pro-inflammatory responses in the lungs of Ifitm3 2/2 mice with levels of TNF-a, IL-6, G-CSF and MCP-1 showing the most marked increase ( Fig. 3c and Supplementary  Fig. 7 ). This is indicative of the extent of viral spread within the lungs, as TNF-a and IL-6 are released from cells upon infection 17 . Consistent with the immunopathology data above, these changes are comparable in level to those seen with non-H5N1 high-pathogenicity influenza infections 9 . Neutrophil chemotaxis, together with elevated proinflammatory cytokine secretion, has previously been reported as one of the primary causes of acute lung injury 18 .
To investigate further the extensive damage observed with lowpathogenicity influenza A virus infection in the absence of IFITM3, we infected both wild-type and Ifitm3 2/2 mice with a PR/8 influenza strain deficient for the multi-functional NS1 gene (delNS1) 19, 20 . NS1 is the primary influenza virus interferon antagonist, with multiple inhibitory effects on host immune pathways 20,21 . We found that delNS1 virus was attenuated in both wild-type and Ifitm3 2/2 mice, and whereas the isogenic PR/8 strain expressing NS1 showed typical high pathogenicity in all mice tested, lower doses of PR/8 influenza (although lethal in both genotypes of mice) caused accelerated weight loss in Ifitm3 2/2 compared to wild-type mice ( Supplementary Fig. 8 ). As delNS1 influenza A virus retains its pathogenicity in IFN-deficient mice 19 , this suggests that Ifitm3 2/2 mice can mount an adequate IFNmediated anti-viral response without extensive morbidity, and that IFITM3 blocking viral replication occurs before NS1-mediated IFN RESEARCH LETTER antagonism 7 . Therefore, unchecked lung viral replication and an enhanced inflammatory response accounts for the profoundly deleterious effects of viral infection in Ifitm3 2/2 mice. The human IFITM3 gene has two exons and is predicted to encode two splice variants that differ by the presence or absence of the first amino-terminal 21 amino acids (Fig. 4a ). Currently, 13 non-synonymous, 13 synonymous, one in-frame stop and one splice site acceptor-altering single nucleotide polymorphisms (SNPs) have been reported in the translated IFITM3 sequence (Supplementary Table 1 ). Using tests sensitive to recent positive selection, we can find evidence for positive selection on the IFITM3 locus in human populations acting over the last tens of thousands of years in Africa (Fig. 4b, c) . We therefore LETTER RESEARCH sequenced 1.8 kilobases of the IFITM3 locus encompassing the exons, intron and untranslated regions from 53 individuals who required admission to hospital as a result of pandemic H1N1/09 or seasonal influenza virus infection in 2009-2010. Of these, 86.8% of patients carried majority alleles for all 28 SNPs in the coding sequence of the gene, but 13.2% possessed known variants. In particular, we discovered over-representation in cases of the synonymous SNP rs12252, wherein the majority T allele is substituted for a minority C allele, which alters the first splice acceptor site and may be associated with the IFITM3 splice variant (ENST00000526811), which encodes an IFITM3 protein lacking the first 21 amino acids due to the use of an alternative start codon. The allele frequencies for SNP rs12252 vary in different human populations (Supplementary Table 2 ). The ancestral (C) allele, reported in chimpanzees, is rare in sub-Saharan African and European populations (derived allele frequency (DAF) 0.093 and 0.026-0.036, respectively), but more frequent in other populations (Supplementary Table 2 ). SNP rs12252 is notable for its high level of differentiation between Europeans and East Asians, although the fixation index (F ST , a measure of population differentiation) does not reach statistical significance. The genotypes associated with rs12252 in Caucasians hospitalized following influenza infection differ significantly from ethnically matched Europeans in 1000 Genomes sequence data and from genotypes imputed against the June 2011 release of the 1000 Genomes phased haplotypes from the UK, Netherlands and Germany (Wellcome Trust Case Control Consortium 1 (WTCCC1, UK): P 5 0.00006, Netherlands: P 5 0.00001, Germany: P 5 0.00007; Fisher's exact test). Patients' genotypes also depart from Hardy-Weinberg equilibrium (P 5 0.003), showing an excess of C alleles in this population (Fig. 4d ). Principal components analysis of over 100,000 autosomal SNPs showed no evidence of hidden population structure differences between WTCCC controls and a subset of the hospitalised individuals from this study ( Supplementary Fig. 9a, b) .
To test the functional significance of the IFITM3 rs12252 polymorphism in vitro, we confirmed the genotypes of HapMap lymphoblastoid cell lines (LCLs) homozygous for either the majority (TT) or minority (CC) variant IFITM3 alleles ( Supplementary Fig. 9c ). We next challenged the LCLs with influenza A virus and found that the minority (CC) variant was more susceptible to infection, and this vulnerability correlated with lower levels of IFITM3 protein expression compared to the majority (TT) variant cells ( Supplementary Fig. 10 ). Although we did not detect the IFITM3 splice variant protein (ENST00000526811) in the CC LCLs, we nonetheless investigated the possible significance of its presence by stably expressing the N-terminally truncated (ND21) and wild-type proteins to equivalent levels in human A549 lung carcinoma cell lines before infection with influenza A virus (A/WSN/1933 (WSN/33)). We found that cells expressing the ND21 protein failed to restrict viral replication when compared to wild-type IFITM3 (Fig. 4e ), consistent with previous data showing that the amino-terminal 21 amino acids of IFITM3 are required for attenuation of vesicular stomatitis virus replication in vitro 4 . Similar results were obtained using other virulent viral strains (A/California/7/2009 (pH1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/60/2008) ( Supplementary Fig. 3 ).
We show here that IFITM3 expression acts as an essential barrier to influenza A virus infection in vivo and in vitro. The fulminant viral pneumonia that occurs in the absence of IFITM3 arises because of uncontrolled virus replication in the lungs, resulting in profound morbidity. In effect, the host's loss of a single immune effector, IFITM3, transforms a mild infection into one with remarkable severity. Similarly, the enrichment of the rs12252 C-allele in those hospitalized with influenza infections, together with the decreased IFITM3 levels and the increased infection of the CC-allele cells in vitro, suggests that IFITM3 also plays a pivotal role in defence against human influenza virus infections. This innate resistance factor is all the more important during encounters with a novel pandemic virus, when the host's acquired immune defences are less effective. Indeed, IFITM3-compromised individuals, and in turn populations with a higher percentage of such individuals, may be more vulnerable to the initial establishment and spread of a virus against which they lack adaptive immunity. In light of its ability to curtail the replication of a broad range of pathogenic viruses in vitro, these in vivo results suggest that IFITM3 may also shape the clinical course of additional viral infections in favour of the host, and may have done so over human evolutionary history.
METHODS SUMMARY
Mouse infection. Wild-type and Ifitm3 2/2 mice 8 (8-10 weeks of age) were intranasally inoculated with 10 4 p.f.u. of A/X-31 (H3N2) influenza, 200 p.f.u. of A/England/195/09 (pH1N1) influenza, or 50-10 3 p.f.u. of A/PR/8/34 (PR/8) or the PR/8 NS1 gene deletion mutant (delNS1) 20 (H1N1) in 50 ml of sterile PBS. Mouse weight was recorded daily as well as monitoring for signs of illness. Mice exceeding 25% total weight loss were killed in accordance with UK Home Office guidelines. Infected lungs were collected on days 1-6 post-infection and quantified for viral load by plaque assay and RT-qPCR with primers to influenza matrix 1 protein.
Pathology of infected Ifitm3 2/2 mice. 5-mm sections of paraffin-embedded tissue were stained with haematoxylin and eosin and microscopically examined. Apoptosis was assessed by TUNEL using the TACS XL DAB In Situ Apoptosis Detection Kit (R&D Systems). Viral RNA was visualized by QuantiGene viewRNA kit (Affymetrix), with a viewRNA probe set designed to the negative stranded vRNA encoding the NP gene of A/X-31 (Affymetrix). Lung tissue was embedded in glycol methacrylate (GMA) and viral antigens stained using M149 polyclonal antibody to influenza A, B (Takara). Single cell suspensions from the lung were characterized by flow cytometry for T-lymphocytes CD4 1 or CD8 1 , T-lymphocytes (activated) CD4 1 CD69 1 or CD8 1 CD69 1 , neutrophils CD11b hi CD11c -Ly6g 1 , dendritic cells CD11c 1 CD11b lo Ly6g lo MHC class II high, macrophages CD11b 1 CD11c 1 F4/80 hi , natural killer cells NKp46 1 CD4 2 CD8 2 . Sequencing and genetics of human IFITM3. The 1.8 kb of human IFITM3 was amplified and sequenced to identify single nucleotide polymorphisms (SNPs). SNP rs12252 was identified and compared to allele and genotype frequencies from 1000 Genomes sequencing data from different populations including 1000 Genomes imputed. SNP rs12252 allele frequencies were determined in the publicly available genotype data sets of WTCCC1 (n 5 2,938) and previously published data sets genotyped from the Netherlands (n 5 8,892) and Germany (n 5 6,253) 22 . Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
